- Home
- VYNE vs GLMD Comparison
VYNE vs GLMD Comparison
Compare VYNE & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- GLMD
- Stock Information
- Founded
- VYNE 2003
- GLMD 2000
- Country
- VYNE United States
- GLMD Israel
- Employees
- VYNE N/A
- GLMD N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- GLMD Health Care
- Exchange
- VYNE Nasdaq
- GLMD Nasdaq
- Market Cap
- VYNE 7.9M
- GLMD 8.0M
- IPO Year
- VYNE 2018
- GLMD 2014
- Fundamental
- Price
- VYNE $0.43
- GLMD N/A
- Analyst Decision
- VYNE Buy
- GLMD Hold
- Analyst Count
- VYNE 2
- GLMD 1
- Target Price
- VYNE $8.00
- GLMD N/A
- AVG Volume (30 Days)
- VYNE 3.1M
- GLMD 71.0K
- Earning Date
- VYNE 11-06-2025
- GLMD 11-13-2025
- Dividend Yield
- VYNE N/A
- GLMD N/A
- EPS Growth
- VYNE N/A
- GLMD N/A
- EPS
- VYNE N/A
- GLMD N/A
- Revenue
- VYNE $476,000.00
- GLMD N/A
- Revenue This Year
- VYNE N/A
- GLMD N/A
- Revenue Next Year
- VYNE N/A
- GLMD N/A
- P/E Ratio
- VYNE N/A
- GLMD N/A
- Revenue Growth
- VYNE N/A
- GLMD N/A
- 52 Week Low
- VYNE $0.28
- GLMD $1.15
- 52 Week High
- VYNE $4.30
- GLMD $4.81
- Technical
- Relative Strength Index (RSI)
- VYNE 60.37
- GLMD N/A
- Support Level
- VYNE $0.32
- GLMD N/A
- Resistance Level
- VYNE $0.35
- GLMD N/A
- Average True Range (ATR)
- VYNE 0.02
- GLMD 0.00
- MACD
- VYNE 0.02
- GLMD 0.00
- Stochastic Oscillator
- VYNE 84.88
- GLMD 0.00
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.